Evidence map›Paper›PMID 41011375›Full record

ArticleMicroorganisms2025

An AI-Designed Antibody-Engineered Probiotic Therapy Targeting Urease to Combat

Feiliang Zhong, Xintong Liu, Xuefang Wang, Mengyu Hou, Le Guo, Xuegang Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Beyond Antibiotics: Alternative Strategies TargetingExpert reviews in molecular medicine · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Feiliang ZhongKey Laboratory of Industrial Fermentation Microbiology of the Ministry of Education, College of Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China.
Xintong LiuKey Laboratory of Industrial Fermentation Microbiology of the Ministry of Education, College of Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China.
Xuefang WangKey Laboratory of Industrial Fermentation Microbiology of the Ministry of Education, College of Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China.
Mengyu HouKey Laboratory of Industrial Fermentation Microbiology of the Ministry of Education, College of Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China.
Le GuoNingxia Key Laboratory of Clinical Pathogenic Microorganisms, School of Laboratory Medicine, Ningxia Medical University, Yinchuan 750004, China.
Xuegang LuoKey Laboratory of Industrial Fermentation Microbiology of the Ministry of Education, College of Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China.

Funding

Key Research and Development Project of Ningxia Hui Autonomous Region 2020BFG02012National Key Research and Development Program Project 2017YFD0400303National Key Research and Development Program Project 2018YFA0901700Tianjin Science and Technology Achievement Transfer and Transformation Project 24ZYCGSY00390
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Ab single-domain antibodiesAI-driven antibody designEscherichia coli Nissle 1917 engineered probioticsflora homeostasisHelicobacter pylori

Identifiers

PMID41011375
PMCPMC12473049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.